245 related articles for article (PubMed ID: 8143024)
1. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
Carrada Bravo T
Rev Alerg; 1993; 40(4):91-4. PubMed ID: 8143024
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
[TBL] [Abstract][Full Text] [Related]
3. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.
Holmgren J; Lycke N; Czerkinsky C
Vaccine; 1993 Sep; 11(12):1179-84. PubMed ID: 8256498
[TBL] [Abstract][Full Text] [Related]
4. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
5. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
Agren LC; Ekman L; Löwenadler B; Nedrud JG; Lycke NY
J Immunol; 1999 Feb; 162(4):2432-40. PubMed ID: 9973526
[TBL] [Abstract][Full Text] [Related]
6. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
7. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
8. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
Lycke N
Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
[TBL] [Abstract][Full Text] [Related]
9. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity.
Nochi T; Yuki Y; Katakai Y; Shibata H; Tokuhara D; Mejima M; Kurokawa S; Takahashi Y; Nakanishi U; Ono F; Mimuro H; Sasakawa C; Takaiwa F; Terao K; Kiyono H
J Immunol; 2009 Nov; 183(10):6538-44. PubMed ID: 19880451
[TBL] [Abstract][Full Text] [Related]
10. [The immunology of cholera and the molecular biology of cholera toxin. Recent progress and future perspectives].
Carrada-Bravo T
Rev Alerg Mex; 1994; 41(3):69-76. PubMed ID: 9377108
[TBL] [Abstract][Full Text] [Related]
11. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
Lebens M; Holmgren J
Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
13. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
Yu X; Ma Q
Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
Agren LC; Ekman L; Löwenadler B; Lycke NY
J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
[TBL] [Abstract][Full Text] [Related]
15. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
Stewart-Tull DE; Lucas C; Bleakley CR
Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
[TBL] [Abstract][Full Text] [Related]
16. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.
Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T
Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283
[TBL] [Abstract][Full Text] [Related]
17. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
Liao J; Gibson JA; Pickering BS; Watnick PI
mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
[TBL] [Abstract][Full Text] [Related]
18. Current status of cholera and rise of novel mucosal vaccine.
Yamamoto T
Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
[TBL] [Abstract][Full Text] [Related]
19. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases.
Langridge W; Dénes B; Fodor I
Curr Opin Investig Drugs; 2010 Aug; 11(8):919-28. PubMed ID: 20721834
[TBL] [Abstract][Full Text] [Related]
20. Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization.
Tomasi M; Dertzbaugh MT; Hearn T; Hunter RL; Elson CO
Eur J Immunol; 1997 Oct; 27(10):2720-5. PubMed ID: 9368632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
